Mo Qatanani, PhD

Recruited as Head of Biology and promoted to Head of Research and subsequently Chief Scientific Officer within two years. Provide enterprise-level scientific and operational leadership in a public-company setting, with accountability for R&D performance, portfolio strategy, and execution. Report to the CEO and engage regularly with the Board, investors, and external stakeholders, contributing to corporate strategy, capital planning, and operating decisions to drive long-term value creation. Key initiatives and impact: ▪ Built and scaled a multidisciplinary Research organization (~30 FTEs; ~$27M annual budget) spanning discovery, protein sciences and antibody engineering, preclinical development, bioanalytical sciences, biomarkers, and toxicology. ▪ Co-founded and co-chaired an enterprise Portfolio Review Committee with the CMO, integrating discovery, development, regulatory, and commercial perspectives to enable disciplined capital allocation, indication sequencing, and program prioritization. ▪ Chaired the Board’s Science, Innovation, and Technology Committee, providing board-level oversight of discovery and clinical portfolios to maximize long-term enterprise and shareholder value. ▪ Partnered with the CEO and CFO on capital strategy and execution, supporting oversubscribed secondary equity financings totaling $100M+ and $300M+; served as a primary scientific spokesperson across investor meetings, non-deal roadshows, and earnings calls. ▪ Played a central role in business development and strategic transactions, including a program spin-out, advancement of an anemia program into a NewCo, fibrosis collaboration opportunities, and maturation of a novel anti-myostatin–GLP-1 fusion for cardiometabolic partnering. ▪ Led portfolio strategy across neuromuscular diseases (SMA, DMD, FSHD, ALS, MG), fibrosis, anemia, oncology, and metabolic diseases, delivering three development candidates and multiple IND filings.

Focus: Founding R&D leader and first employee, leading platform and pipeline creation, neuromuscular disease strategy, capital formation, and scientific and organizational build-out from company inception through IPO. Key initiatives and impact: ▪ First employee and founding scientific leader, personally recruited by founder and CEO Romesh Subramanian to Atlas Venture to build Dyne’s platform, pipeline, and organization from inception. ▪ Built and scaled Dyne’s R&D organization from the ground up, recruiting and leading 25 scientists from senior research associates through Senior Director level, personally driving early discovery and translational execution, and establishing a high-ownership, execution-driven culture grounded in scientific rigor, accountability, and speed. ▪ Reported directly to the CEO and COO and served as a core scientific representative to the board and investors, contributing to seed money tranche pull downs, $50M Series A, $115M Series B, and a $268M IPO, and supporting investor, board, and patient-advocacy engagements. ▪ Held portfolio-level scientific and program leadership across Dyne’s three lead programs (DMD, DM1, and FSHD), driving disease strategy and indication prioritization through KOL engagement, third-party research, competitive and market assessment, and cross-functional decision-making during the company’s early growth phase. ▪ Led the discovery and translational research that generated Dyne’s lead clinical candidates, including DYNE-101 (DM1) and DYNE-251 (DMD), advancing programs from concept through development candidate selection, IND-enabling studies, and clinical planning. ▪ Led the DMD program from development candidate selection through IND filing and clinical entry, securing FDA alignment on preclinical, clinical, and biomarker strategy, including a potential path toward accelerated approval, while directing nonclinical development and regulatory engagement.

Focus: Post-acquisition integration, rare disease discovery and translational research, research organization consolidation, external partnerships, and team leadership. Key initiatives and impact: ▪ Led the post-acquisition integration of Synageva’s early-stage pipeline and research teams into Alexion’s R&D organization, formulating and defending program rationales to new executive leadership and shaping portfolio strategy, governance, and investment priorities. ▪ Led consolidation of Alexion’s research organization, facilitating closure of three research sites in GA and MA to refocus resources and capabilities at the New Haven site, strengthening operational efficiency and strategic alignment. ▪ Conceived and led Alexion’s blood–brain barrier (BBB) research strategy, securing a $2M budget and orchestrating a multi-site, cross-functional effort that evaluated and advanced 14 internal and external technologies. ▪ Built and led a five-program early-stage rare disease portfolio (protein replacement and RNA-based approaches in collaboration with Moderna), owning strategy, timelines, sourcing, and pre-IND planning; mentored program leads in end-to-end program and external collaboration leadership and delivered preclinical proof of concept for four programs within 18 months, including recommendations on target prioritization and portfolio strategy to the executive team. ▪ Transitioned Alexion Research into a more externally facing, partner-enabled organization, leading the “Partner of Choice” initiative and chairing the Discovery Partnerships Scientific Review Committee to strengthen governance, compliance, and portfolio discipline amid a >50% budget reduction to $12M.

Recruited to build the early-stage pipeline for rare disease therapeutics. Established and cultivated external partnerships to swiftly move rare disease therapeutic research programs throughout the drug development lifecycle. Key initiatives and impact: ▪ Built and advanced 7 early-stage rare disease programs spanning lysosomal storage disorders, hemophilia, hereditary angioedema, vasculitis, and inherited metabolic liver diseases, from concept through IND-enabling studies. ▪ Led translational research strategy and execution with ownership of a $5M budget, rapidly converting discovery concepts into development-ready programs. ▪ Established and managed an externally driven development model, leveraging CRO and academic partnerships to accelerate execution across a broad, multi-program portfolio. ▪ Delivered preclinical proof of concept for three programs within one year, contributing to pipeline depth and scientific validation supporting Synageva’s $8.4B acquisition by Alexion.

Brought in to provide vision and leadership to advance early-stage drug discovery programs focused on small molecules and peptide therapies for diabetes. Advanced the internal programs and brought in 3 additional external programs by orchestrating the most significant discovery research collaboration in the diabetes department. Key initiatives and impact: ▪ Led early-stage discovery programs in diabetes and inflammatory diseases across small molecules, peptides, and GPCR targets, advancing multiple assets into early development portfolios. ▪ Directed a $3.75M external collaboration with Richard DiMarchi, advancing a peptide lead series to preclinical candidate selection and generating additional series that later seeded a new biotechnology company. ▪ Designed and executed a discovery strategy for once-weekly, thermostable peptide therapeutics, delivering rapid preclinical proof of concept for Fc-fusion peptides while establishing high-impact academic collaborations (including Massachusetts General Hospital) and supporting translational strategy and portfolio entry decisions.

Conducted research at the laboratory of Dr. Mitchell Lazar. ▪ Developed and characterized several novel humanized mouse models that helped delineate the role of the hormone resisting in linking inflammation to the etiology of diabetes and associated diseases.

Conducted research at the laboratory of Dr. David Moore. ▪ Discovered the role of the constitutive androstane receptor in mediating drug metabolism in type I diabetes and investigated the mechanisms of drug-induced decrease in bone mineral density.

▪ Conducted research at the laboratory of Dr. David Moore ▪ Discovered a novel mechanism of drug induced thyroid cancer and established mouse models that helped identify a mechanism of nuclear hormone receptor mediated drug-hormone interactions during pregnancy.

▪ Conducted research at the laboratory of Dr. Laila Zahed ▪ Identified the genetic mutations that correlate with the severity of phenotype in patients with Beta-Thalassemia.